Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IPH-6101 by Innate Pharma for Myelodysplastic Syndrome: Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
IPH-6101 by Innate Pharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
IPH-6101 by Innate Pharma for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
IPH-6101 by Innate Pharma for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...